Telemedicine-based inspiratory muscle training and walking promotion with lung cancer survivors following curative intent therapy: a parallel-group pilot randomized trial
- PMID: 37656252
- PMCID: PMC10474183
- DOI: 10.1007/s00520-023-07999-7
Telemedicine-based inspiratory muscle training and walking promotion with lung cancer survivors following curative intent therapy: a parallel-group pilot randomized trial
Abstract
Purpose: Following curative-intent therapy of lung cancer, many survivors experience dyspnea and physical inactivity. We investigated the feasibility, acceptability, safety, and potential efficacy of inspiratory muscle training (IMT) and walking promotion to disrupt a postulated "dyspnea-inactivity" spiral.
Methods: Between January and December 2022, we recruited lung cancer survivors from Kaiser Permanente Colorado who completed curative-intent therapy within 1-6 months into a phase-IIb, parallel-group, pilot randomized trial (1:1 allocation). The 12-week intervention, delivered via telemedicine, consisted of exercise training (IMT + walking), education, and behavior change support. Control participants received educational materials on general exercise. We determined feasibility a priori: enrollment of ≥ 20% eligible patients, ≥ 75% retention, study measure completion, and adherence. We assessed acceptability using the Telemedicine-Satisfaction-and-Usefulness-Questionnaire and safety events that included emergency department visits or hospitalizations. Patient-centered outcome measures (PCOMs) included dyspnea (University-of-California-San-Diego-Shortness-of-Breath-Questionnaire), physical activity (activPAL™ steps/day), functional exercise capacity (mobile-based-six-minute-walk-test), and health-related quality of life (HRQL, St.-George's-Respiratory-Questionnaire). We used linear mixed-effects models to assess potential efficacy.
Results: We screened 751 patients, identified 124 eligible, and consented 31 (25%) participants. Among 28 participants randomized (14/group), 22 (11/group) completed the study (79% retention). Intervention participants returned > 90% of self-reported activity logs, completed > 90% of PCOMs, and attended > 90% of tele-visits; 75% of participants performed IMT at the recommended dose. Participants had high satisfaction with tele-visits and found the intervention useful. There was no statistically significant difference in safety events between groups. Compared to control participants from baseline to follow-up, intervention participants had statistically significant and clinically meaningful improved HRQL (SGRQ total, symptom, and impact scores) (standardized effect size: -1.03 to -1.30).
Conclusions: Among lung cancer survivors following curative-intent therapy, telemedicine-based IMT + walking was feasible, acceptable, safe, and had potential to disrupt the "dyspnea-inactivity" spiral. Future efficacy/effectiveness trials are warranted and should incorporate IMT and walking promotion to improve HRQL.
Trial registration: ClinicalTrials.gov NCT05059132.
Keywords: Dyspnea; Exercise; Patient-centered outcomes; Rehabilitation; Survivorship; Telemedicine; Telerehabilitation.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The authors declare no competing interests.
All authors declare that no conflict of interest exists. Dr. Malhotra is funded by NIH. He reports income related to medical education from Jazz, Zoll, Eli Lilly and Livanova. ResMed provided a philanthropic donation to the University of California San Diego.
Figures
References
Publication types
MeSH terms
Associated data
Grants and funding
- R01 HL157985/HL/NHLBI NIH HHS/United States
- R01 AG077011/AG/NIA NIH HHS/United States
- T32 HL134632/HL/NHLBI NIH HHS/United States
- R21 CA256656/CA/NCI NIH HHS/United States
- R01HL154926/HL/NHLBI NIH HHS/United States
- IK2 RX003661/RX/RRD VA/United States
- R01NR018479/NR/NINR NIH HHS/United States
- UL1 TR002535/TR/NCATS NIH HHS/United States
- T32 HL166127/HL/NHLBI NIH HHS/United States
- R01AG077011/AG/NIA NIH HHS/United States
- R01 HL166485/HL/NHLBI NIH HHS/United States
- R01 AG063925/AG/NIA NIH HHS/United States
- P30 CA023100/CA/NCI NIH HHS/United States
- 3UL1TR002535/NH/NIH HHS/United States
- R01 HL154926/HL/NHLBI NIH HHS/United States
- R01 HL148436/HL/NHLBI NIH HHS/United States
- R21CA256656/CA/NCI NIH HHS/United States
- R01 NR018479/NR/NINR NIH HHS/United States
